STIM Quote, Financials, Valuation and Earnings

Alphatec Holdings has a net margin of -39.64% compared to Neuronetics's net margin of -30.68%. Neuronetics's return on equity of -189.86% beat Alphatec Holdings's return on equity of -691.37%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 59.29%. On the other hand Alphatec Holdings has an analysts' consensus of $18.21 which suggests that it could grow by 39.74%. Given that Neuronetics has higher upside potential than Alphatec Holdings, analysts believe Neuronetics is more attractive than Alphatec Holdings.

Neuronetics has a beta of 1.919, which suggesting that the stock is 91.876% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.249%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are smaller than Alphatec Holdings quarterly revenues of $169.2M. Neuronetics's net income of -$12.7M is higher than Alphatec Holdings's net income of -$51.9M. Notably, Neuronetics's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.91x versus 2.93x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

electroCore has a net margin of -39.64% compared to Neuronetics's net margin of -57.38%. Neuronetics's return on equity of -189.86% beat electroCore's return on equity of -163.87%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 59.29%. On the other hand electroCore has an analysts' consensus of $21.88 which suggests that it could grow by 293.96%. Given that electroCore has higher upside potential than Neuronetics, analysts believe electroCore is more attractive than Neuronetics.

Neuronetics has a beta of 1.919, which suggesting that the stock is 91.876% more volatile than S&P 500. In comparison electroCore has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.354%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are larger than electroCore quarterly revenues of $6.7M. Neuronetics's net income of -$12.7M is lower than electroCore's net income of -$3.9M. Notably, Neuronetics's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.91x versus 1.58x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

Milestone Scientific has a net margin of -39.64% compared to Neuronetics's net margin of -89.35%. Neuronetics's return on equity of -189.86% beat Milestone Scientific's return on equity of -79.98%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 59.29%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 108.33%. Given that Milestone Scientific has higher upside potential than Neuronetics, analysts believe Milestone Scientific is more attractive than Neuronetics.

Neuronetics has a beta of 1.919, which suggesting that the stock is 91.876% more volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Neuronetics's net income of -$12.7M is lower than Milestone Scientific's net income of -$2M. Notably, Neuronetics's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.91x versus 9.49x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -39.64% compared to Neuronetics's net margin of -35.24%. Neuronetics's return on equity of -189.86% beat Myomo's return on equity of -38.11%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 59.29%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 164.62%. Given that Myomo has higher upside potential than Neuronetics, analysts believe Myomo is more attractive than Neuronetics.

Neuronetics has a beta of 1.919, which suggesting that the stock is 91.876% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $32M, which are larger than Myomo quarterly revenues of $9.8M. Neuronetics's net income of -$12.7M is lower than Myomo's net income of -$3.5M. Notably, Neuronetics's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.91x versus 3.45x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.